Report cover image

Middle East mRNA Synthesis Raw Material Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA), By Application, By End Use, By Country, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Oct 31, 2025
Length 150 Pages
SKU # GV20575229

Description

Market Size & Trends

The Middle East mRNA synthesis raw material market size was valued at USD 51.8 million in 2024 and is expected to reach USD 77.3 million by 2033, expanding at a CAGR of 4.73% from 2025 to 2033. The market is driven by the increasing acceptance of mRNA-based therapeutics and vaccines, the expansion of biopharmaceutical manufacturing capacity, and the growing investment in genomic and molecular research in the region.

Rising adoption of mRNA-based vaccines And therapeutics

One of the main factors driving the growth of the mRNA synthesis raw material market is the increasing demand for mRNA-based vaccines and therapeutics. The historic performance of mRNA vaccines during the COVID-19 pandemic has confirmed the technological effectiveness documented in initial R&D efforts and the scalability and flexibility of mRNA "as a platform" to redefine modern medicine. This positive momentum in R&D activity generated demand for raw materials to prepare high-quality mRNA-associated products, with increased need for raw materials, such as nucleotides, capping reagents, enzymes, and lipid excipients, for mRNA synthesis and formulation.

Moreover, the increasing pipeline of mRNA therapeutics moving into clinical trials promotes long-term market growth. Governments and international health organizations are also supporting mRNA vaccine development programs to improve pandemic preparedness and fulfill other unmet medical needs. The expanding use of mRNA technologies for personalized and precision medicine, primarily in cancer immunotherapy, continues to generate ongoing demand for tailored, GMP-grade synthesis materials. Collectively, the common clinical acceptance of mRNA and diversification of its uses is becoming more evident as an important market component of next-generation therapeutic innovation.

Middle East mRNA Synthesis Raw Material Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the Middle east mRNA synthesis raw material market on the basis of type, application, end-use, and country.
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Capping Agents
  • CleanCap Reagents
  • ARCA (Anti-Reverse Cap Analog)
  • Others
  • Nucleotides
  • Modified Nucleic Acids
  • N1-methylpseudouridine-triphosphate
  • 5-Methylcytidine triphosphate (5mCTP)
  • Natural Nucleic Acids
  • Adenine
  • Guanine
  • Cytosine
  • Uracil
  • Plasmid DNA
  • Enzymes
  • Polymerase
  • RNase Inhibitor
  • DNase
  • Others
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Vaccine Production
  • Therapeutics Production
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • CROs & CMOs
  • Academic & Research Institutes
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman
  • Rest of Middle East
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Type Segment
1.2.2. Application Segment
1.2.3. End Use Segment
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Middle East mRNA Synthesis Raw Materials Market Variables & Trends
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Advancements in mRNA technology
3.2.1.2. Rising adoption of mRNA-based vaccines and therapeutics
3.2.2. Market restraint analysis
3.3. Middle East mRNA Synthesis Raw Materials Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Middle East mRNA Synthesis Raw Materials Market: Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. Middle East mRNA Synthesis Raw Materials Market Type Movement Analysis
4.3. Middle East mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Capping Agents
4.4.1. Capping agents market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. CleanCap Reagents
4.4.2.1. CleanCap reagents market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. ARCA (Anti-Reverse Cap Analog)
4.4.3.1. ARCA (Anti-Reverse Cap Analog) market estimates and forecasts 2021 to 2033 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Nucleotides
4.5.1. Nucleotides market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2. Modified nucleic acids
4.5.2.1. Modified nucleic acids market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2.2. N1-methylpseudouridine-triphosphate
4.5.2.2.1. N1-methylpseudouridine-triphosphate market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2.3. 5-Methylcytidine triphosphate (5mCTP)
4.5.2.3.1. 5-Methylcytidine triphosphate (5mCTP) market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2.4. Others
4.5.2.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3. Natural nucleic acids
4.5.3.1. Natural nucleic acids market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.2. Adenine
4.5.3.2.1. Adenine market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.3. Guanine
4.5.3.3.1. Guanine market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.4. Cytosine
4.5.3.4.1. Cytosine market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.5. Uracil
4.5.3.5.1. Uracil market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Plasmid DNA
4.6.1. Plasmid DNA market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Enzymes
4.7.1. Enzymes market estimates and forecasts 2021 to 2033 (USD Million)
4.7.2. Polymerase
4.7.2.1. Polymerase market estimates and forecasts 2021 to 2033 (USD Million)
4.7.3. RNase Inhibitor
4.7.3.1. RNase inhibitor market estimates and forecasts 2021 to 2033 (USD Million)
4.7.4. DNase
4.7.4.1. DNase market estimates and forecasts 2021 to 2033 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Middle East mRNA Synthesis Raw Materials Market: Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. Middle East mRNA Synthesis Raw Materials Market Application Movement Analysis
5.3. Middle East mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Vaccine Production
5.4.1. Vaccine production market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Therapeutics Production
5.5.1. Therapeutics production market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Middle East mRNA Synthesis Raw Materials Market: End Use Estimates & Trend Analysis
6.1. End Use Segment Dashboard
6.2. Middle East mRNA Synthesis Raw Materials Market End Use Movement Analysis
6.3. Middle East mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical & Pharmaceutical Companies
6.4.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
6.5. CROs & CMOs
6.5.1. CROs & CMOs market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Academic & Research Institutes
6.6.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Middle East mRNA Synthesis Raw Material Market: Regional Estimates & Trend Analysis
7.1. Country Market Share Analysis, 2023 & 2033
7.2. Country Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. Middle East
7.4.1. Saudi Arabia
7.4.1.1. Key country dynamics
7.4.1.2. Competitive scenario
7.4.1.3. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.4.2. UAE
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.4.3. Kuwait
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
7.4.4. Qatar
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
7.4.5. Oman
7.4.5.1. Key country dynamics
7.4.5.2. Competitive scenario
7.4.5.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
7.4.6. Rest of Middle East
7.4.6.1. Key country dynamics
7.4.6.2. Competitive scenario
7.4.6.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Company Profiles/Listing
8.4.1. F. Hoffmann-La Roche Ltd.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Service benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Jena Bioscience GmbH
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Merck KGaA
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. BOC Sciences
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Thermo Fisher Scientific, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Maravai LifeSciences
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. New England Biolabs
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Creative Biogene
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. HONGENE
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Service benchmarking
8.4.10.4. Strategic initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us